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Several immunological epitopes are known to be located within the Friend murine leukemia virus (F-MuLV) envelope
protein, but their relative contributions to protection from Friend virus-induced disease are not known. To determine how
expression of various immunological determinants affected protection, mice were immunized with recombinant vaccinia
viruses expressing different portions of the F-MuLV envelope protein, and they were then challenged with a lethal dose of
Friend virus complex. The disease parameters that were followed in the mice were early viremia, early splenomegaly, and
late splenomegaly. Both the N-terminal and C-terminal portions of the F-MuLV gp70 were found to protect against late
splenomegaly, the primary clinical sign associated with virus-induced erythroleukemia. However, neither region alone
protected against early splenomegaly and early viremia, indicating poor immunological control over early virus replication
and spread through the spleen and blood. In contrast, mice immunized with a vaccine expressing the entire F-MuLV envelope
protein were protected against all three disease parameters. The results indicated that expression of multiple immunological
determinants including both T-helper and B cell epitopes was necessary for full protection. © 1998 Academic Press
INTRODUCTION
The development of an HIV vaccine has been one of the
major challenges of AIDS research. Progress has been
hindered by the lack of a small animal model, but a great
deal of basic information has been gained by studies of SIV
in primates, FIV in cats, and murine leukemia viruses such
as MAIDS and Friend virus (FV) in mice. The FV model has
been particularly useful for elucidating various host genes
involved in protective immunity to retroviral disease (Chese-
bro et al., 1990; Hasenkrug and Chesebro, 1997), for testing
the efficacy of various vaccines (Hunsmann et al., 1981;
Kleiser et al., 1986; Miyazawa et al., 1992, 1995; Ruan and
Lilly, 1992), and for determining host mechanisms of pro-
tection in vaccinated animals (Hasenkrug et al., 1996). Both
neutralizing antibody and CTL responses correlate with
protection from FV infection (Earl et al., 1986), and both are
thought to be necessary responses for an HIV vaccine as
well (Cease and Berzofsky, 1994; Bolognesi, 1996). Most
successful human vaccines, including those for polio,
smallpox, measles, mumps, and rubella, are based on live
attenuated viruses, which are very effective at eliciting both
antibody and CTL responses. However, the use of live
attenuated viruses is thought to be unsafe for HIV, mainly
because of the possibility that mutations or recombinations
might produce virulent strains. One possible solution is to
express immunogenic subunits in live recombinant vectors
such as vaccinia, adeno- or polioviruses. We have used this
approach to study protection from FV-induced erythroleu-
kemia in adult immunocompetent mice.
Recombinant vaccinia viruses expressing either the gag
or envelope proteins of the Friend murine leukemia virus
(F-MuLV) helper virus have been shown to protect suscep-
tible (B10.A 3 A.BY)F1 mice from FV-induced erythroleukemia
(Earl et al., 1986; Miyazawa et al., 1990). Since immuniza-
tion with the envelope protein conferred a higher level of
protection than gag, we have been interested in defining the
protective determinants within the envelope protein and
studying how immunization with these determinants affects
disease. The current experiments demonstrate protective
determinants in both the N-terminal and C-terminal regions of
the envelope protein. The N-terminal determinants were found
to be important for protection from viremia and late spleno-
megaly but did not completely prevent early virus replication
as evidenced by early splenomegaly. Vaccination with the
C-terminal determinants gave long-term protection from late
splenomegaly but did not protect from either early viremia
or early splenomegaly. Thus, the data indicate that a com-
bination of determinants from both the N-terminal and C-
terminal regions was necessary for full protection.
RESULTS
Localization of protective determinants to the
C-terminal portion of F-MuLV gp70
Three criteria were used to judge the efficacy of vac-
cination. The first criterion was protection from spleno-1 To whom correspondence should be addressed.
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megaly at 6–8 weeks postinfection (late splenomegaly).
Late splenomegaly is associated with FV-induced eryth-
roleukemia (Wendling et al., 1981), which is usually fatal
(Fig. 1). The second two criteria were protection from
early splenomegaly and early viremia, which are related
to the degree of early virus replication and spread in the
spleen and blood, respectively. Early splenomegaly at 2
weeks postinfection is due to polyclonal proliferation of
erythroid precursor cells stimulated by FV infection (Li et
al., 1990; Hoatlin and Kabat, 1995). Spread of virus to the
blood and consequent viremia have been shown in sev-
eral experiments to be controlled by virus-neutralizing
antibody responses such that the levels of viremia and
the virus-neutralizing antibody titers are inversely related
(Chesebro et al., 1974; Chesebro and Wehrly, 1979; Britt
and Chesebro, 1983; Hasenkrug et al., 1995). Late vire-
mia was not studied because even unvaccinated mice of
this strain develop virus-neutralizing antibody responses
by 3 weeks postinfection and clear viremia despite on-
going splenomegaly. Thus, only early viremia titers re-
flect the ability of the various vaccines to prime the
virus-neutralizing antibody response.
Greater than 90% of the mice immunized with recom-
binant vaccinia virus expressing the F-MuLV envelope
protein (vvF-MuLV, Fig. 2) were protected from late
splenomegaly (Fig. 3A). Furthermore, most of these mice
developed no early splenomegaly following challenge
with FV (Fig. 3A), and only 1 of 18 mice had a severely
affected spleen rated at 31 (Fig. 4). In addition, no
viremia was detectable in plasma samples taken from
these mice at 1–2 weeks postinfection, and all mice had
detectable virus-neutralizing antibodies (Table 1). Thus,
vvF-MuLV was a highly protective and effective vaccine
in this strain of mice. Conversely, most mice immunized
with the nonprotective vvF-MCF envelope (Fig. 2) be-
came grossly splenomegalic following challenge with FV
(Fig. 4), developed high viremia titers (Table 1), and failed
to recover from disease (Fig. 3A). vvF-MCF was derived
from an in vivo recombination between an endogenous
retroviral sequence and exogenous F-MuLV at or near
the p15E junction (Koch et al., 1984). Thus, vvF-MCF and
vvF-MuLV have almost identical p15E sequences that
differ by a single amino acid residue at position 482.
vvF-MCF contains none of the immunological epitopes
shown in Fig. 2, and its failure to protect indicates that
the shared p15E regions do not encode protective deter-
minants.
To delineate regions of the F-MuLV envelope impor-
tant for protection, three chimeric envelope genes that
contained combinations of protective F-MuLV sequences
and nonprotective F-MCF sequences were constructed
(Fig. 2). As shown previously (Hasenkrug et al., 1996),
vaccination with vvCh1 produced high levels of protec-
tion from late splenomegaly (8 week post-challenge), but
a higher percentage of mice had early splenomegaly (2
weeks post-challenge) than was observed in mice vac-
cinated with vvF-MuLV (Fig. 3A). Similar results were
obtained from vaccination studies with the new chimeric
envelope vaccines, vvCh2 and vvCh3 (Fig. 3A). In addi-
tion to higher percentages of mice with early splenomeg-
aly, the degree of splenomegaly was more severe in
mice vaccinated with the chimeric envelopes than in
vvF-MuLV-vaccinated mice. For example, more than half
of the vvCh3-vaccinated mice had severe splenomegaly
(31 and 41 spleens) at 2 weeks postinfection (Fig. 4).
Another indication that the chimeric vaccines worked
less well than vvF-MuLV was the presence of viremia
(Table 1). Thus, although protective determinants impor-
tant for long-term protection from splenomegaly were
found to be located between the AvrII and PstI sites in
the F-MuLV envelope, the results indicated that addi-
tional immunological determinants important for early
protection were located in the N-terminal region, up-
stream of the EcoRI site (Fig. 2).
Protective determinants in the N-terminal portion of
F-MuLV gp70
Two approaches were used to test the N-terminal
region for protective determinants. First, a chimeric en-
velope gene recombined at the EcoRI site was con-
structed to encode N-terminal F-MuLV and C-terminal
F-MCF sequences. Unfortunately, this construct did not
express a detectable envelope protein, and protection
studies could not be done (data not shown). As a second
approach, we used an in-frame BstEII deletion mutant of
F-MuLV in which the central region and part of the
C-terminal region of gp70 was removed (Bst D1, Fig. 2).
To control for effects from remaining C-terminal se-
FIG. 1. Splenomegaly and death in unvaccinated (B10.A 3 A.BY)F1
mice. Thirty-three age-matched (B10.A 3 A.BY)F1 mice were infected
by intravenous inoculation with a high dose (1500 SFFU) of FV. Palpa-
tions for splenomegaly were done as described in Materials and
Methods. The percentage of splenomegalic mice (solid line) includes
those mice that were splenomegalic when they died. The percentage of
dead mice (dashed line) includes terminally ill mice that were eutha-
nized when observed to show signs of suffering.
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quences, we constructed Bst D2, which differed from Bst
D1 only at the N-terminal region. As was the case with
the chimeric envelope constructs tested for protection,
these deletion constructs expressed envelope proteins
at levels equivalent to or greater than vvF-MuLV (data not
shown). Protection studies showed good recovery from
splenomegaly and long-term protection with vvBst D1,
which expressed the N-terminal region of F-MuLV (Fig.
3B). Furthermore, no viremia was detected between 1
and 2 weeks post-challenge in vvBst D1-vaccinated mice
(Table 1). However, more than half of the mice were
affected by early splenomegaly (Fig. 3B), some with se-
vere (31 and 41) splenomegaly (Fig. 4). These results
indicated that the N-terminal region of F-MuLV gp70
contained determinants important for protection from
both late splenomegaly and viremia but not sufficient to
control early splenomegaly.
In contrast, results from mice vaccinated with vvBst D2
showed poor protection from late splenomegaly (Fig. 3B),
and most of the mice had early viremia as well (Table 1).
Thus, the C-terminal region of gp70 and the p15E region,
both shared by the two deletion mutants, were not suf-
ficient to induce high levels of long-term protection. How-
ever, statistical analysis of late splenomegaly in vvBst
D2-vaccinated mice showed marginal but significant pro-
tection compared with the control vaccine, vvF-MCF (p 5
0.039, Fig. 3). In addition, two of eight vvBst D2-vacci-
nated mice showed no detectable viremia and made
virus-neutralizing antibody responses (Table 1), an indi-
cation that the vaccine affected disease progression in
those animals. These data are consistent with a weak
immunological effect from the T-helper epitope in C-
terminal region of gp70 (Fig. 2). Taken as a whole, the
data did not show any evidence for protective epitopes in
the p15E region of F-MuLV env.
DISCUSSION
Immunization with vvF-MuLV provides high levels of
protection from FV-induced early splenomegaly, viremia,
FIG. 2. Viral env constructs used in vaccines. Recombinant envelope genes were constructed as described in Materials and Methods. Restriction site
abbreviations are A, AvrII; B, BstEII; C, ClaI; E, EcoRI; and P, PstI. Open bars designate F-MuLV-derived sequences and hatched bars represent F-MCF-derived
sequences. Th1 and Th2 are described T-helper epitoipes of sequences DEPLTSLTPRCNTAWNRLKL and HPPSYVYSQFEKSYRHKR, respectively (Iwashiro et al.,
1993). These designations do not refer to type 1 or type 2 T-helper responses. B1 is an F-MuLV envelope-specific epitope for mAb 48 (Chesebro et al., 1981) known
to be encoded by sequences 59 of the EcoRI site, but the exact location is unknown and its exact placement in the N-terminal portion of the molecule is arbitrary.
B2 is an F-MuLV envelope-specific epitope for mAb 720 (Robertson et al., 1991) encoded by sequences between the AvrII and BstEII sites as shown. The F-MuLV
env gene encodes a CTL epitope (Robertson et al., 1992), most likely located between the two BstEII sites (Ruan and Lilly, 1991). Its exact location is not known.
Constructs recombined into vaccinia vectors are designated by a ‘‘vv’’ prefix.
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and terminal erythroleukemia. The current studies show
that such protection is complex and dependent on ex-
pression of multiple immunological determinants located
throughout the envelope protein. Vaccines expressing
only portions of the F-MuLV-derived envelope sequence
were less effective at preventing early splenomegaly and
viremia after challenge, but the mice were later able to
recover from acute infection and did not develop eryth-
roleukemia. Thus, immunoprotective determinants were
found in both the N-terminal region of gp70 upstream of
the BstEII site and in the C-terminal region between the
AvrII and PstI sites. However, only the combination of
both regions protected from early disease as well as
fatal erythroleukemia.
The ability of a vaccine to prevent early virus spread is
of major importance in any retroviral vaccine. For RNA
viruses such as retroviruses, which do not have proof-
reading capability in their polymerase, increased repli-
cation leads to increased mutation and accumulation of
mutations leads to a greater likelihood of immunological
escape (Coffin, 1995; Bangham and Phillips, 1997). This
problem is evident from studies done in HIV infections,
where mutation of immunological epitopes has been
associated with progression to AIDS (Phillips et al., 1991;
Nowak et al., 1995; Borrow et al., 1997; Goulder et al.,
1997; Price et al., 1997). Wide virus dissemination early in
infection also leads to an increased likelihood of persis-
tence, which could potentially lead to T cell depletion
and AIDS in HIV and SIV infections (McCune, 1995).
Recombinant vaccinia vaccines in the SIV model have
not been successful in protecting monkeys from infection
and AIDS (Giavedoni et al., 1993; Daniel et al., 1994), and
such protection failure may have been due in part to lack
of sufficient immunological epitopes to provide early
control over virus replication. The studies presented here
indicate that a multiplicity of T helper and B cell epitopes
is an important aspect in such early control.
The current results demonstrate that vaccinia-based
FIG. 3. Vaccine-induced protection from FV-induced erythroleukemia. Age-matched female (B10.A 3 A.BY)F1 mice were vaccinated by tail scratch
with 107 pfu of the recombinant vaccinia viruses. The mice were challenged 1 month later by intravenous inoculation with a high dose (1500 SFFU)
of FV. (A) Splenomegaly (21 or greater) in mice vaccinated with parental and chimeric envelope vaccines: for vvFMuLV, n 5 52; vvF-MCF, n 5 34;
vvCh1, n 5 20; vvCh2, n 5 33; vvCh3, n 5 12. (B) Splenomegaly (21 or greater) in mice vaccinated with the envelope deletion constructs: for vvBst
D-1, n 5 13; vvBST D-2, n 5 43. Chi-square analysis was used to compare protection by vvF-MCF and vv Bst D-2 and yielded a P value 5 0.039 by
Fisher’s exact test. Eighteen mice from the vvBst D-2 goup were followed long-term for fatality and 12 were dead or had to be euthanized by 90 days
postinfection (67%). This figure closely agrees with the 60-day splenomegaly data for the group as a whole.
FIG. 4. Severity of splenomegaly in individual vaccinated and FV-
challenged mice. The degree of splenomegaly in individual mice from
representative groups in the protection experiments is shown. Spleno-
megaly was rated as described in Fig. 5 ranging from normal (11) to
very severe (41). Each increasing numerical value represents an ap-
proximate doubling of spleen size.
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expression of a single T-helper epitope provides very
poor long-term protection from erythroleukemia (37%
protection from vvBst D2). However, expression of a B
cell epitope in addition to the T-helper epitope improved
protection to 95% (compare vvBst D2 with vvCh1 in Fig.
2). The two B cell epitopes (B1 and B2 in Fig. 2) may differ
in their ability to control early viremia because vaccina-
tion with vvBst D1 containing the B1 epitope protected
better than vvCh1 with the B2 epitope (Table 1). Alterna-
tively, the effect may have been due to better priming of
the antibody response because vvBst D1 had two T
helper epitopes while vvCh1 had only a single T helper
epitope. Although vaccination with vvBst D1 provided
protection from early viremia, it did not protect from early
splenomegaly as well as vvF-MuLV. This finding indi-
cated that the central gp70 region that was deleted from
vvBst D1 contained important immunological epitopes.
One possibility is the CTL epitope previously reported to
lie in this region (Ruan and Lilly, 1991). Although the
peptide described in that report does not prime target
cells for lysis in our system (data not shown), it is still
possible that the central region contains a CTL epitope.
The presence of a CTL epitope could be very important
for early protection, but the addition of the central region
to vvCh3, which also contained a T helper and B cell
epitope, still did not give protection from early spleno-
megaly. We previously showed that vaccination with
vvCh1, which does not include a CTL epitope, nonethe-
less primes for a rapid CTL response following challenge
with FV (Hasenkrug et al., 1996). Thus one might only
expect a kinetic difference in the development of the CTL
responses dependent on the presence of a CTL epitope.
Interestingly, data from Miyazawa et al. suggest that
the lack of a B cell epitope can be compensated by the
use of adjuvant. Significant long-term protection was
obtained using injections of synthetic peptides with com-
plete Freund’s adjuvant (Miyazawa et al., 1995). The pep-
tides had the sequences of the envelope-encoded T-
helper epitopes shown in Fig. 2 (Iwashiro et al., 1993;
Shimizu et al., 1994). It is known that adjuvants can
enhance immune responses, and this has specifically
been demonstrated in the FV system (Ishihara et al.,
1992). The current data suggest that an important aspect
of adjuvants in protection from FV may be to either
stimulate or simulate a B cell function important for
priming the immune response. An example of such a
function would be antigen presentation to T helper cells,
either stimulated by adjuvant or, alternatively, compen-
sated for by a different type of antigen presenting cell.
The potential of peptides as human vaccines is limited
because any given peptide can be presented to the
immune system by only a small subset of major histo-
compatibility complex (MHC) molecules. One solution to
this problem is subunit vaccines, which express entire
proteins and thus increase the likelihood of a peptide/
MHC match. However, the current data indicate that
even when antigenic protein sequences are matched
with the corresponding MHC molecules, a multiplicity of
antigen epitopes may be required to prevent virus infec-
tion and spread. Thus, rather than attempting to express
the minimal number of antigenic epitopes in a retroviral
vaccine, the expression of the maximal number of viral
proteins may provide the highest protection in a popula-
tion with diverse MHC types
MATERIALS AND METHODS
Mice
In this study, age- and sex-matched (B10.A 3 A.BY)F1
mice of 3–6 months of age at experimental onset were
TABLE 1













vvF-MuLV 8/52 (15) 1.2 0/7 12/12 4/52 (8)
vvF-MCF 33/34 (97) 3.5 6/6 1/11 29/34 (85)
vvCh1 8/20 (40) 1.6 2/7 5/12 1/20 (5)
vvCh2 11/33 (33) 1.8 4/8 6/9 4/33 (12)
vvCh3 8/12 (58) 2.3 6/8 4/8 0/12 (0)
vvBstD1 8/13 (62) 1.8 0/7 7/7 1/13 (8)
vvBstD2 30/43 (70) 2.9 6/8 2/10 27/43 (63)
a Animals with splenomegaly at 2 weeks post-challenge, indicative of virus replication in the spleen.
b Severity of splenomegaly at 2 weeks post-infection as described in Fig. 5.
c Viremia was measured at 1–2 weeks post-challenge as described in the Materials and Methods section. The limit of detection was 220
focus-forming units (ffu) per ml. All viremic mice had greater than 1000 ffu/ml.
d Number of mice with virus-neutralizing antibody titers greater than 1:2 at 1–2 weeks post-challenge.
e Animals splenomegalic at 8 weeks postinfection, indicative of terminal erythroleukemia as shown in Fig. 1.
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used. Parental strains were obtained from the Jackson
Laboratories and breeding of F1 strains was done at
Rocky Mountain Laboratories. Relevant Friend virus re-
sistance genotypes in (B10.A 3 A.BY)F1 mice are H-2a/b,
Fv-1b/b, Fv-2r/s, and Rfv-3r/s (Chesebro et al., 1990). The
mortality studies shown in Fig. 1 are from previously
unpublished experiments. In accordance with our cur-
rent policy to prevent suffering in experimental animals,
death is no longer used as an endpoint for such studies.
All mice were treated in accordance with NIH regula-
tions and the guidelines of the Animal Care and Use
Committee of Rocky Mountain Laboratories.
Virus and virus infections
The Friend virus complex used in these experiments
was an uncloned virus stock obtained from a 10% spleen
cell homogenate from Balb/c mice infected 9 days pre-
viously with a B-tropic, polycythemia-induced FV strain
originally obtained from Dr. Frank Lilly (Chesebro et al.,
1974). In virus challenge experiments, mice were injected
intravenously with 0.5 ml of phosphate buffered, bal-
anced salt solution containing 2% fetal bovine serum and
1500 spleen focus-forming units of Friend virus complex.
Splenomegaly as a measure of Friend disease
Palpation for splenomegaly is the standard procedure
used to follow progression of Friend disease (Chesebro
et al., 1974; Earl et al., 1986; Polsky and Lilly, 1991) and
was used in the following manner: at weekly intervals,
each individual animal under general anesthesia was
palpated in a blinded fashion and rated on a scale of 11
to 41 according to its spleen size (Fig. 5). Mice with
sustained splenomegaly for greater than 6 weeks gen-
erally have 31 or 41 spleens, and there is no ambiguity
in making this determination. Such mice also display
additional hallmarks of erythroleukemia such as hemat-
ocrits greater than 85%, high numbers of erythroid pre-
cursors in the blood, and fully transformed tumor cells
(Wendling et al., 1981). As shown in Fig. 1, mice that still
have sustained splenomegaly by 6–8 weeks postinfec-
tion begin to die about 10 weeks postinfection, and most
are dead by 16 weeks postinfection. In contrast, mice
that recover from splenomegaly live normal lifespans
(Chesebro et al., 1974, 1979).
Viral env constructs used vaccines
The F-MuLV env used in the vaccines was derived
from clone 57 (Oliff et al., 1980) and the F-MCF env was
from clone 54B (Oliff et al., 1983). Construction of Ch1
has been described (Hasenkrug et al., 1996). Ch2 was a
recombination of Ch1 with a PstI/ClaI fragment from
F-MCF. An EcoRI site was constructed into F-MuLV env
by site-directed overlap mutagenesis, and the EcoRI/ClaI
fragment was inserted into F-MCF to produce Ch3. Bst
D-1 (also known as MR4, Iwashiro et al., 1993) and Bst
D-2 were in-frame deletions of F-MuLV and Ch3 respec-
tively. The vaccinia recombinants (designated vv) used
for vaccination in these studies were produced as de-
scribed (Earl et al., 1986). Expression of each of the
constructs was assayed by SDS-polyacrylamide gel
electrophoresis of proteins immunoprecipitated from re-
combinant vaccinia virus-infected CV1 cells using a rab-
bit anti-p15E antiserum. The expression of each of the
proteins was equivalent to or greater than that of vvF-
muLV (data not shown).
Viremia and virus-neutralizing antibody assays
For viremia assays, freshly frozen plasma samples
were titrated by focal infectivity assays (Sitbon et al.,
1985) on susceptible Mus dunni cells (Lander and Chat-
topadhyay, 1984) pretreated with 4 mg/ml Polybrene. Cul-
tures were incubated for 5 days, fixed with ethanol,
stained with F-MuLV envelope-specific mAb 720 (Robert-
son et al., 1991), and developed with goat anti-mouse
peroxidase conjugated antisera (Cappel, West Chester,
PA) to detect foci. To test plasma samples for virus-
neutralizing antibodies, heat-inactivated (56°C, 10 min)
samples at titrated dilutions were incubated with virus
stock in the presence of complement at 37°C as previ-
ously described (Morrison et al., 1987). The samples
were then plated as described for the viremia assay to
determine the dilution at which 90% of the virus had been
neutralized.
FIG. 5. FV-induced splenomegaly. Spleens were obtained from an
uninfected (B10.A 3 A.BY)F1 adult mouse, and four FV-infected mice
that were rated for splenomegaly by palpation as indicated. The
weights of the spleens are shown above each organ. Normal (11)
spleen weights range from 0.1 to 0.25 g. Spleens greater than twice
normal size (more than 0.4 g) but not large enough to reach the ventral
midline were rated as 21. Experienced personnel can easily distin-
guish such spleens from normal spleens. Spleens large enough to
reach the ventral midline were rated as 31 (weight between 0.8 and
1.6 g). Spleens that extended across the abdominal midline, and
caused protrusion of the abdominal wall were rated as 41 (weight
greater than 1.6 g). Although mice that have recovered from FV-induced
splenomegaly generally have spleens larger than normal (spleen on far
right), they weigh less than 0.4 g and are judged as 11. Cross-checking
of actual spleen weights with spleen sizes determined by palpations
has demonstrated consistency in differentiating spleens weighing in
the normal weight range from those weighing greater than 0.4 g (21)
(Chesebro et al., 1979; unpublished data).
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